Caladrius Biosciences EPS beats by $0.04
- BySeeking Alpha-
Caladrius Biosciences (CLBS): Q2 GAAP EPS of -$0.10 beats by $0.04.Revenue of $43.29M (+138.1% Y/Y)Press Release
Symbol | Exchange | Currency |
|---|
Caladrius Biosciences (CLBS): Q2 GAAP EPS of -$0.10 beats by $0.04.Revenue of $43.29M (+138.1% Y/Y)Press Release
BASKING RIDGE, N.J., June 22, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company...
BASKING RIDGE, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Buy | Neutral | Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 148.79 | 148.97 | 147.22 | -0.24 | -0.16% | 67.85M | NASDAQ | |||
| 373.06 | 373.56 | 369.71 | -0.86 | -0.23% | 11.57M | NASDAQ | |||
| 2,872.20 | 2,886.00 | 2,848.00 | -16.4 | -0.57% | 1.28M | NASDAQ | |||
| 18.90 | 19.38 | 17.31 | +2.11 | +12.57% | 10.39M | NYSE | |||
| 44.47 | 44.99 | 44.03 | -0.30 | -0.67% | 22.12M | NYSE | |||
| 14.90 | 15.15 | 13.02 | +1.62 | +12.20% | 45.66K | NASDAQ | |||
| 30.73 | 31.65 | 30.70 | -0.83 | -2.63% | 955.04K | NYSE | |||
| 133.07 | 133.30 | 129.70 | +1.98 | +1.51% | 1.11M | NASDAQ | |||
| 41.71 | 42.42 | 41.25 | -0.45 | -1.07% | 697.24K | NYSE | |||
| 1.13 | 1.14 | 1.11 | 0.0000 | 0.00% | 510.94K | NASDAQ | |||
| 5.31 | 5.39 | 5.28 | -0.010 | -0.19% | 12.31K | NASDAQ | |||
| 5.68 | 5.835 | 5.50 | -0.480 | -7.79% | 13.10M | NYSE | |||
| 15.55 | 16.89 | 15.46 | -1.360 | -8.04% | 6.66M | NYSE | |||
| 219.01 | 219.45 | 218.60 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 6.07 | 6.13 | 5.995 | +0.010 | +0.17% | 20.83K | NASDAQ |
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).